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Abstract. A Geant4 Monte Carlo simulation study was carried out to characterise a novel silicon
strip detector, the Dose Magnifying Glass (DMG), for use in proton therapy Quality Assurance.
We investigated the possibility to use DMG to determine the energy of the incident proton beam.
The advantages of DMG are quick response, easy operation and high spatial resolution. In this
work we theoretically proved that DMG can be used for QA in the determination of the energy
of the incident proton beam, for ocular and prostate cancer therapy. The study was performed by
means of Monte Carlo simulations Experimental measurements are currently on their way to
confirm the results of this simulation study.

1. Introduction
While proton radiotherapy has experienced a growth in the number of operational facilities and an
increase in capabilities of beam delivery technology, there has been a substantial lack of development
in commercial detectors for related Quality Assurance (QA). In particular, fast verification of the beam
energy, range in water and position of the characteristic pristine or spread out Bragg Peak in both a pretreatment and real time setting is necessary to prevent radiation accidents and deliver treatment to the
patient safely, minimising the damage to healthy tissues and critical structures. Ideally detectors used in
proton therapy QA should provide sub-millimetre spatial resolution determination of proton range over
a wide energy range to resolve the steep energy gradient of the Bragg Peak and be able to provide this
information at a sub-second temporal resolution.
Currently, the generation of available detectors implemented for proton therapy QA include
ionization chambers, as recommended by the ICRU Report 78 and IAEA TRS-398 [1, 2], single diodes
and films to derive the Bragg Peak position in water phantoms [3].
The Dose Magnifying Glass (DMG) is a silicon strip detector developed by the Centre of Medical
Radiation Physics (CMRP) at the University of Wollongong. It is a miniature detector for use in proton
therapy QA, with applications into X-ray stereotactic radiosurgery (SRT) and intensity modulated
radiotherapy (IMRT) investigated previously demonstrating the DMG capability to provide submillimetre spatial resolution at a sub-second temporal resolution over a large (103) dynamic range [4].
Its advantages over existing commercial QA detectors include the simple device operation and high
spatial resolution over a wide dynamic energy range, required to resolve the Bragg Peak accurately.
This paper presents the Monte Carlo characterisation of the DMG as device to determine the
energy of the incident proton beam for ocular and prostate cancer proton therapy treatment. At this stage,
the principle of operation is proved for mono-energetic proton beams only.

Content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence. Any further distribution
of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
Published under licence by IOP Publishing Ltd
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2. Dose Magnifying Glass
The DMG is a 128 channel p-silicon strip detector, with each strip consisting of a sensitive implanted
n+ area of 20x2000 μm, separated by a pitch of 200 μm. This detector, in singular configuration, is
mounted upon a thin Kapton carrier, as presented in figure 1, which provides a convenient connection
of the 128 channels to a FPGA based multichannel electrometer, resulting in a total size of 4x28x0.25
mm. In serial configuration an additional detector, providing a further 128 channels, is positioned 4 mm
behind the first, rotated 180° and translated such that the sensitive volumes remain aligned in both
detectors. In this configuration the detectors are mounted upon a PCB board with the entire ensemble
placed in a housing consisting of a 75x95x5 mm PMMA lower half and a RMI457 Solid Water top half
with a wax recess for the detectors.

Figure 1. Singular configuration of the
DMG mounted on a Kapton Carrier.

Figure 2. Serial configuration of the DMG mounted on a PCB
board with wax recess and solid water housing shown.

Range Difference
(mm)

3. DMG Principle of operation in pre-treatment QA to determine incident proton beam energy
When the device is positioned appropriately in the treatment target region in a water phantom, protons
directly incident on the DMG produce a first Bragg Peak in the device. Other protons, instead, scatter
in the phantom and in the detector packaging before entering in the DMG, producing a second Bragg
Peak at a further depth. The distance between the two Bragg Peaks can be measured and uniquely
related to the kinetic energy of the proton beam when incident on the device, using the CSDA range
difference, shown in figure 3.
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Figure 3. CSDA range
difference of protons
traversing silicon and
PMMA/Polystyrene.

Once the energy E DMG of the proton beam at the entrance of DMG is determined, the energy of
the incident beam, E inciden t at the entrance of the phantom can be calculated by considering the associated
CSDA range of protons, R CSDA . By applying formula 1, E incident can be derived:
𝑅𝑅𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 (𝐸𝐸𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 ) = 𝑅𝑅𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 (𝐸𝐸𝐷𝐷𝐷𝐷𝐷𝐷 ) + 𝑥𝑥𝑥𝑥,

(1)

where x is the path length and ρ the density of the phantom, traversed by the incident proton beam before
entering the DMG. If different materials are traversed before entering in DMG, formula 1 has to be
applied to obtain the energy of the proton beam E incident at the entrance of each specific material.
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4. Methodology
Geant4 based simulations [5] were developed to prove the principle of operation of DMG for QA in
ocular and prostate proton therapy. The DMG was modelled accurately in terms of geometry and
materials. A proton beam of 62 MeV and 129.46 MeV was adopted for ocular and prostate cancer
treatment, respectively. In both cases the proton beam is incident along the major axis of the DMG. To
describe particle interactions in the simulation toolkit, the Livermore Data Libraries were adopted to
model the electromagnetic interactions, while the QGSP_BIC_HP Physics list was adopted to describe
hadronic interactions. The threshold of production of secondary particles was fixed to 0.01 mm. The
energy deposition produced by the incident proton beam and its secondary particles was recorded in the
silicon strip detectors.
4.1. Simulation application for Ocular Cancer Therapy QA
In the case of pre-treatment QA in proton therapy for ocular melanoma, a 62 MeV proton beam was
simulated with particles generated at -20 mm in air. A beam radius varying between 1 and 15 mm was
adopted to study its effect on the response of the detector. The detector was positioned within a PMMA
spherical phantom with radius equal to 18 mm, modelling a simplified anatomy of the eye while
remaining large enough to house the detector as shown in figure 4.
4.2. Simulation Application for Prostate Cancer Therapy QA
A 129.46 MeV proton beam was selected to model the beam energy of the first experimental
measurements with DMG, performed by the CMRP and collaborators at the Massachusetts General
Hospital, Boston. In this simulation, a polystyrene target of varying thickness (70.9 mm, 81.1 mm and
91.3 mm) was positioned in front of the DMG with polystyrene scattering blocks placed above and
below the DMG, as shown in figure 5.

Figure 4. Simplified schematic of the
simulation application setup for ocular cancer
therapy QA.

Figure 5. Simplified schematic of the simulation application
setup for prostate cancer therapy QA.

5. Results
5.1. DMG for Ocular Cancer Therapy QA
Figure 6 shows the DMG response with an incident beam of 62 MeV protons, with different beam radius.
The energy deposition is calculated in the silicon strip detectors and then converted to depth in the DMG.
Two distinct Bragg Peaks are observed in the detector response. As the beam radius increases, a
greater number of protons scatter into the silicon sensitive strips, following the interactions in the
surrounding PMMA phantom. This translates in a higher second Bragg Peak in DMG.
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Figure 6. Response of the DMG
to a mono-energetic 62MeV
proton beam.

From the detector response, the distance between the two Bragg Peaks is determined to be 9.7 mm,
corresponding to an energy of 60 MeV at the DMG entrance. Using the methodology outlined in section
3 the initial energy of the beam is determined to be approximately 62 MeV when entering in the
phantom. This value agrees with the energy of the proton beam input to the simulation.
5.2. Application for Prostate Cancer Therapy QA
Response of the DMG in serial configuration to mono-energetic 129.46 MeV protons incident along the
major axis of the detector is presented in figure 7 for the polystyrene thicknesses investigated. The range
difference of Bragg Peaks is presented in Table 1 alongside with the calculated proton incident energy
at the DMG entrance and the phantom entrance, derived using the method described in section 3. For
polystyrene thickness of 70.9 mm, as the second peak occurs in the detector region of no response,
analysis is unviable.

Figure 7. Response of the DMG in
serial configuration to mono-energetic
129.46 MeV protons. In serial
configuration a physical gap causes a
region of no energy detection.

Table 1. Application for Prostate Cancer Therapy Results. E DMG is the energy of the proton beam at the
entrance of DMG. E incident is the energy of the proton beam at the entrance of the phantom.

Polystyrene Target
Thickness (mm)
81.1
91.3

Peak Range Difference
(mm)
13.2
6.4

E DMG (MeV)

E incident (MeV)

61.25
41.25

131.6
128.9

6. Discussion and conclusions
The results of this work demonstrate the applicability of the DMG in pre-treatment QA to determine the
energy of the incident proton beam.
The proof of principle has been demonstrated for ocular cancer therapy QA, with sharp, easily
identifiable pristine Bragg Peaks observed in the detector response. This means that DMG in principle
may be used to accurately resolve the initial beam energy, as demonstrated by the agreement in
determined initial beam energy and injected particle energy.
When comparing the case of prostate cancer proton therapy against the treatment of ocular cancer,
with a higher proton energy the position of the Bragg Peaks results to be less resolved as protons traverse
a larger number of different materials surrounding the detector. This leads to a larger error in determining
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the distance between the Bragg Peaks measured by the DMG. Despite these effects, our study shows
that the energy of the incident beam can be resolved in principle with an error of ~1 MeV for a monoenergetic proton beam.
In conclusion this work proved the principle of operation of DMG for pre-treatment QA in proton
therapy for the determination of the proton beam energy. CMRP is currently undertaking experimental
measurements with collaborators at the Massachusetts General Hospital to prove this principle of
operation.
In the near future, the simulation results shown in this paper will be compared to the experimental
measurements. The simulations will be repeated with a Spread Out Bragg Peak to verify the principle
of operation in this case as well.
7. Acknowledgments
The author wishes to thank the financial support provided by Prince of Wales Hospital Radiation
Oncology Trust Fund, without which research would not have been able to be undertaken.
8. References
[1] ICRU 2007 Prescribing, Recording and Reporting Proton-Beam Therapy (Report 78) J. ICRU 7
[2] IAEA 2000 Absorbed Dose Determination in External Beam Therapy: An International Code of
Practice for Dosimetry Based on Standards of Absorbed Dose to Water Technical Report Series
No. 398
[3] Hill R F et al 2008 Rad. Meas. 43 1258-64
[4] Wong J H D et al 2010 Med. Phys. 37 427-39
[5] 2014 “GEANT4 User’s Guide for Application Developers (Version: GEANT4 10.1)”, GEANT4
Collaboration

5

